Loading the section
Closing prices for 09 October 2026
Next earnings report: 02 November 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Krystal Biotech, Inc. trades on Nasdaq under the ticker KRYS. The company belongs to the Health care sector. The trading history on this page starts on 20 September 2017.
Over the past 52 weeks KRYS has traded between 179.19 $ and 382.54 $. As of 09 October 2026 the price stood 74.96 % of the way from the 52-week low to the high.
Over one year KRYS shares rose 77.16 %; over six months they rose 28.03 %. Volatility over 90 days is 40.23 %. Dividends are not included: this is price change only, as of 09 October 2026.
KRYS trades at a price-to-earnings ratio of 43.3, above the sector median of 24.8. Price to sales is 23.3, above the sector median of 3.9. Price to book is 7.6, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 326.55 | 333.44 | 323.87 | 331.61 | 196,947 |
| 08 October 2026 | 321.61 | 332.11 | 319.58 | 327.30 | 271,500 |
| 07 October 2026 | 324.87 | 330.44 | 320.20 | 324.57 | 354,100 |
| 06 October 2026 | 335.16 | 335.16 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Krystal Biotech treats an inherited skin disease with a gene therapy applied like a gel.
Gene therapy is usually a one-off hospital procedure with demanding preparation. Here it is different: a viral vector carrying a working copy of the gene is applied directly to the wound, and the procedure is repeated regularly. That changes both the logistics and the economics — treatment becomes a course rather than a single event.
The condition is rare and severe: the skin tears at the slightest touch, and no treatment existed at all. The company is profitable, which is unusual for a developer of this kind. What follows depends on applying the same platform in other areas — ophthalmology and lung disease. Risks: the narrowness of the current market, reimbursement and new trial outcomes. The company pays no dividend.
Address:2100 WHARTON STREET SUITE 701, PITTSBURGH, PA, 15203, US
Krystal Biotech, Inc. reported revenue of 417M $ and net income of 225M $ over the last four quarters. Net margin is 53.92 %. Revenue changed by +25.15 % year over year. Earnings per share are 7.47 $. Market capitalisation is 9.7B $.
KRYS has a return on equity of 17.63 %, above the sector median of −41.68 %. Return on assets is 16.11 %, above the sector median of −32.11 %. Operating margin is 42.85 %, above the sector median of −26.84 %.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| HALOHalozyme Therapeutics, Inc. | 111.70 | +1.69 % | 251M |
| BIIBBiogen Inc. | 226.01 | +3.47 % | 224M |
| TECHBio-Techne Corp | 72.46 | +0.01 % | 215M |
| 319.61 |
| 326.81 |
| 352,000 |
| 05 October 2026 | 323.76 | 339.69 | 321.37 | 334.85 | 337,000 |
| 02 October 2026 | 326.75 | 329.22 | 320.29 | 322.28 | 425,600 |
| 01 October 2026 | 332.51 | 334.52 | 325.22 | 325.31 | 225,700 |
| 30 September 2026 | 336.56 | 337.03 | 331.80 | 332.56 | 268,300 |
| 29 September 2026 | 334.62 | 338.48 | 331.78 | 335.06 | 225,800 |
| 28 September 2026 | 347.00 | 350.00 | 334.01 | 337.08 | 298,900 |
| 25 September 2026 | 346.34 | 347.74 | 341.90 | 345.82 | 200,000 |
| 24 September 2026 | 341.85 | 345.48 | 336.56 | 344.96 | 222,500 |
| 23 September 2026 | 353.84 | 353.84 | 337.58 | 341.75 | 215,900 |
| 22 September 2026 | 334.76 | 353.83 | 334.31 | 350.88 | 274,500 |
| 21 September 2026 | 339.48 | 341.15 | 332.44 | 333.85 | 210,300 |
| 18 September 2026 | 340.00 | 341.35 | 335.50 | 336.67 | 1M |
| 17 September 2026 | 340.99 | 343.33 | 335.50 | 338.75 | 280,900 |
| 16 September 2026 | 337.53 | 346.20 | 334.73 | 336.67 | 251,800 |
| 15 September 2026 | 339.01 | 340.09 | 331.80 | 336.68 | 225,800 |
| 14 September 2026 | 349.14 | 352.55 | 339.25 | 340.03 | 288,500 |